Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 78

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 78
---
 FDA IND application, CD47 has great potential in this growing market, especially given its importance as a therapeutic target.

Furthermore, Liminatus’s strategic collaborations with institutions and their focus on in-licensing promising therapeutic assets to broaden their pipeline demonstrate their commitment to staying at the forefront of technological advancements in the field.

Through the Business Combination with Liminatus, we can leverage its innovative technologies to address significant unmet medical needs in cancer therapy on a global scale. Liminatus’s portfolio of highly promising assets and strategic vision to become a global biopharmaceutical leader make it an ideal candidate for international expansion within the growing market for disruptive technologies in oncology.

Steady Growth Business with High Revenue Potential

We focused on investments whose growth potential is backed by adoption of technology and whose end product can be consumed by the growing middle-class population. We viewed growth as an important driver of value and sought companies whose growth potential could generate meaningful upside potential.

The Iris Board believes that Liminatus’s growth potential is backed by a growing immuno-oncology market. Additionally, the Iris Board believes that the presence of multiple biotechnology and pharmaceutical companies pursuing programs in this sector demonstrates the potential to generate high revenues.

Strong Management Background

We intended to acquire a business that has an experienced management team with a proven track record for producing rapid growth and with an ability to clearly and confidently articulate the business and market opportunities to public market investors. As such, we spent significant time assessing a company’s leadership and personnel, and evaluating what we can do to augment and/or upgrade the team over time as needed.

<div align='center'>12</div>

TABLE OF CONTENTS

The Iris Board believes that Liminatus has an experienced management team with a proven track record of collaboration with pharmaceutical companies, research institutions, and academic centers — all which help validate Liminatus’s development efforts. The Iris Board believes that the management team has the ability to clearly and confidently articulate the business and market opportunities of Liminatus to public market investors.

Efficient Use of Capital to Meet Growth Objectives

We sought businesses that we believed were at an inflection point where the utilization of our capital could further propel the expansion of their business to the next operating level. We spent significant time assessing a company’s growth plans and projections to understand how our capital translated to operating growth and investor returns over the long-term.

The Iris Board believes that Liminatus is at an inflection point where the utilization of additional capital can propel the next stage of development. This belief comes from the Iris